1
Indications & Patient Selection
Primary lung cancer, pulmonary metastases, chest wall malignancy, contraindications
Indications
- Primary lung cancer (Stage I NSCLC) — T1a–T1b N0M0; medically inoperable (poor PFTs, COPD, cardiac comorbidities) or patient refuses surgery; ≤3 cm preferred
- Pulmonary metastases — colorectal cancer, sarcoma, melanoma, RCC; oligometastatic (≤5 lesions); resection-refractory or patient preference
- Chest wall malignancy — primary (Askin, Ewing) or metastatic rib lesions with pain
Contraindications
- Central location (<1 cm from central airways or great vessels)
- Lesion abutting heart or pericardium
- Severe COPD (FEV1 <30% predicted)
- Bullous disease at entry site
- Single functioning lung
- Uncorrectable coagulopathy (INR >1.5, platelets <50K)
Best Candidates
- Peripheral tumors (outer one-third of lung parenchyma)
- Lesion size ≤3 cm; optimal ≤2 cm for highest local control rates
- ≥1 cm from bronchi and major vessels
- No endobronchial component
Required Workup
- CT chest — lesion characterization, size, location, vascular proximity
- PET-CT — staging, exclude occult metastatic disease
- PFTs (FEV1 / DLCO) — assess pulmonary reserve
- Bronchoscopy / biopsy if lesion uncharacterized
- INR, CBC with platelets
2
Pre-Procedure Checklist
Modality selection, positioning, equipment, coagulation
Planning & Setup
- CT guidance required — interventional CT suite; CT fluoroscopy or step-and-shoot
- Modality selection: RFA (RITA, Covidien Cool-Tip), MWA (Neuwave 17G), or cryo (small peripheral tumors, near hilum)
- Positioning: prone or lateral decubitus; ipsilateral side down minimizes pleural bleeding and keeps ablated tissue dependent
- Chest tube kit available (20–24 Fr) — pneumothorax incidence 20–40%
- Hydrodissection: 5% dextrose (D5W) for chest wall and diaphragm protection
Anesthesia & Labs
- Local anesthesia + moderate sedation for parenchymal ablation
- General anesthesia for chest wall / rib lesions
- INR <1.5; platelets >50K; hold anticoagulation per SIR guidelines
- Concurrent biopsy if histology unconfirmed — coaxial technique preferred
CT review complete. Lesion size, location, and distance from central airways, vessels, diaphragm, and chest wall documented.
Modality selected. Ablation system (RFA / MWA / cryo) confirmed available and set up; manufacturer protocol reviewed.
Coagulopathy corrected. INR ≤1.5 and platelets ≥50K confirmed before proceeding.
Chest tube kit at bedside. 8–14 Fr small-bore and 20–24 Fr large-bore kits available in room.
D5W available for hydrodissection if lesion within 1 cm of diaphragm or chest wall.
Consent obtained. Key risks discussed: pneumothorax (20–40%), hemorrhage, bronchopleural fistula, local recurrence, need for chest tube, possible hospital admission.
Biopsy plan confirmed. Coaxial access planned if concurrent biopsy needed; pathology notified.
3
Relevant Anatomy
Peripheral vs central, fissures, heat sink, airway clearance
Peripheral vs Central Zones
- Peripheral (outer 1/3 of lung) — safer for ablation; lower risk of airway injury; standard approach
- Central (inner 1/3, near hilum) — high-risk zone; thermal injury to bronchi causes bronchial stenosis, bronchopleural fistula, or massive hemoptysis; reserve for carefully selected cases
- Minimum clearance from left/right main bronchi and lobar bronchi: >1 cm required
Fissures & Vascular Structures
- Fissures: avoid transgressing major or minor fissures — significantly increases pneumothorax risk
- Heat sink effect: vessels >3 mm cause incomplete ablation at adjacent margins; probe repositioning and overlapping ablations needed near major vessels
- Diaphragm / pleural proximity: ablation within 1 cm of diaphragm or pleura requires D5W hydrodissection
Procedural Anatomy Summary
The lung parenchyma is divided into peripheral (outer one-third) and central (inner two-thirds near hilum) zones for ablation planning. Peripheral tumors are ideal: probe trajectories avoid crossing fissures, and no major airways or vessels are jeopardized. Central tumors near the hilar vessels and major bronchi require additional planning, often disqualifying them from ablation entirely. The diaphragm and chest wall serve as key hydrodissection targets when the lesion is within 1 cm — 5% dextrose (not saline) is used because it does not conduct radiofrequency current and provides electrical insulation. Pulmonary vessels >3 mm adjacent to the ablation zone act as heat sinks, cooling the tissue and producing incomplete margins; MWA has less susceptibility to heat sink than RFA due to higher energy deposition rates.
4
Step-by-Step Technique
CT-guided percutaneous ablation with RFA, MWA, or cryoablation
1
Positioning & CT Planning Scan
Position patient ipsilateral side up (or prone for posterior lesions). Obtain CT planning scan. Identify lesion, measure size, confirm distance from airways, vessels, diaphragm, and chest wall. Plan access trajectory avoiding fissures, major vessels, and scapula or rib obstruction. Mark skin entry.
2
Local Anesthesia & Skin Entry
Sterile prep and drape. Infiltrate local anesthesia (lidocaine 1%) from skin through intercostal space down to pleural surface. Instruct patient in breath-hold technique for probe insertion. Advance introducer or coaxial needle to pleural surface under CT guidance, then advance in a single smooth breath-hold into lesion.
3
Probe Placement
Advance ablation probe coaxially to lesion center under CT guidance. Confirm probe tip is within the lesion on CT. For coaxial biopsy: advance coaxial needle to lesion, obtain core biopsy through inner needle, then advance ablation probe through the same coaxial access. Send specimen to pathology before ablation.
▶ Probe placement in lower lobe mass
Probe placement in lower lobe mass: CT confirms probe tip in tumor center — plan for 5–10 mm margin beyond tumor edge; adjust for respiratory motion.
4a
Radiofrequency Ablation (RFA)
Deploy active tines (expandable probe) or ensure straight-tip probe is centered in lesion. Ramp up power per manufacturer protocol (typically 50 W increasing to 200 W over 1–2 min). Ablate until roll-off or target temperature reached. Allow probe to cool before retraction. Reposition if ablation zone is insufficient.
4b
Microwave Ablation (MWA)
Activate at 65 W × 5–10 min per probe position. MWA produces larger ablation zones than RFA and is less affected by heat sink from pulmonary vasculature. For tumors >2 cm, plan overlapping probe positions to achieve ≥1 cm margin. No cooling required between activations if repositioning immediately.
5
Post-Ablation CT
Acquire CT immediately after ablation. Confirm ground-glass opacity (GGO) halo surrounds the entire lesion — must extend ≥1 cm beyond lesion margin in all directions to confirm adequate coverage. Measure ablation zone dimensions and compare to pre-procedure tumor size. Document any pneumothorax.
6
Pneumothorax Management
Classify on post-procedure CT: small (<15% hemithorax) and asymptomatic → observe; repeat CT in 2h. Symptomatic or >15% → place small-bore chest tube (8–14 Fr) via Seldinger technique. Large (>1/3 hemithorax) or tension → large-bore tube (20–24 Fr) immediately. If pneumothorax identified during ablation: complete ablation first (if patient stable), then treat.
7
Recovery & Discharge
Recover 2–4 h. Obtain upright chest X-ray at 1h and 2h. Admit if pneumothorax present, significant pain, or oxygen requirement. Discharge criteria: stable CXR, O2 sat ≥95% on room air, pain controlled, no chest tube in place (or tube removed after water-seal observation).
Ablation Modality Comparison — Lung Tumors
| Feature | RFA | MWA | Cryoablation |
|---|---|---|---|
| Heat sink effect | Significant (major limitation near vessels) | Minimal (higher energy deposition) | Moderate (ice ball may be preserved) |
| Ablation zone | Smaller; variable; affected by impedance roll-off | Larger; more reproducible; sphere-shaped | Visible ice ball on CT; excellent real-time control |
| Real-time monitoring | Temperature / impedance; indirect | Indirect (CT confirmation) | Direct visualization of ice ball on CT |
| Chest wall safety | Risk of neuropathy / pain if probe near chest wall | Risk of thermal injury; D5W hydrodissection needed | Safest near chest wall; ice ball protective for nerves |
| Main lung limitation | Heat sink, roll-off in aerated lung | Charring at probe tip if power too high | Longer procedure; freeze-thaw cycles required; bronchopleural fistula risk near airways |
| Preferred for | Standard peripheral tumors ≤2 cm | Preferred modality; tumors up to 3 cm; near vessels | Small peripheral; near hilum; chest wall |
Community Cards
Sign in to view and create community cards
5
CT Landmarks
GGO halo, cavitation, target sign, pneumothorax measurement
Immediate Post-Ablation Findings (Normal)
- Ground-glass opacity (GGO) halo — surrounds treated lesion; represents reactive inflammation and hemorrhage; a 1-cm GGO halo around the entire lesion = adequate margin; this is the primary adequacy endpoint
- Cavitation — seen with RFA; thin-walled cavity within ablation zone; normal post-ablation change; does NOT indicate recurrence if thin-walled and stable or regressing
- GGO progressively retracts on follow-up scans over 3–6 months; stable retraction = treatment success
Follow-up Findings (Concerning)
- "Target sign" on follow-up CT — central low density (necrosis) + peripheral rim enhancement = local recurrence; biopsy recommended to confirm before re-treatment
- Growing soft tissue nodule at ablation margin — local progression; compare to prior CT; PET-CT may help differentiate from post-ablation fibrosis
- New or enlarging enhancement at 3-month or 6-month follow-up CT → local recurrence until proven otherwise
Pneumothorax Assessment on CT
| Size | Definition | Management |
|---|---|---|
| Small | <15% of hemithorax (thin rim; <2 cm at apex) | Conservative; serial CXR at 1h and 2h; observe in recovery |
| Moderate | 15–33% of hemithorax; >1/3 of lateral chest wall | Small-bore chest tube (8–14 Fr) if symptomatic; consider tube if increasing |
| Large / Increasing | >33% of hemithorax or actively enlarging on serial imaging | Chest tube required; 20–24 Fr if large or tension physiology present |
6
Troubleshooting
Intraoperative problems and solutions
Pneumothorax During Ablation
Air Accumulates in Pleural Space While Ablation In Progress
If small and patient is stable: complete the ablation first, then treat the pneumothorax. If large or tension physiology develops (hypoxia, tracheal deviation, hemodynamic compromise): stop ablation immediately and place chest tube emergently. After treatment is complete, resume ablation if margins were inadequate and patient can tolerate continued procedure.
Probe Cannot Reach Lesion
Rib, Scapula, or Bony Structure Obstructs Needle Path
Change access angle: use a more cranial or caudal intercostal space; angulate the needle craniocaudally within the same interspace. For posterior lesions obstructed by scapula: position arm above head to rotate scapula laterally. Consider an anterior or lateral approach. If all standard approaches fail, a transfissural or translobar trajectory may be necessary with increased pneumothorax counseling.
Insufficient Ablation Zone
GGO Halo Does Not Achieve ≥1 cm Margin on Post-Ablation CT
Perform a second overlapping ablation: reposition the probe to the undertreated margin and ablate again. For MWA, multiple overlapping activations are well tolerated. For RFA, allow probe to cool to avoid impedance roll-off before repositioning. Document final coverage on CT and report the percentage of margin achieved. If margin still inadequate at a central/hilar location, SBRT referral is appropriate.
Lesion Not Visible (Tumor Haze)
Ground-Glass Opacity or Inflammatory Change Obscures Target Lesion
Fuse the current procedural CT with the pre-procedure planning CT using CT workstation co-registration. Use tracked electromagnetic navigation (e.g., LungPoint) if available. Target the center of the GGO region that corresponds to the original solid nodule position. If completely invisible, abort ablation and reschedule after GGO resolves; do not ablate a target that cannot be confirmed.
Hemoptysis During Ablation
Patient Coughs Blood During or After Probe Activation
Minor blood-streaking: expected and normal; reassure patient; continue ablation with observation. Significant hemoptysis (frank blood, >a few mL): stop ablation immediately; roll patient to affected side (bleeding side down); notify anesthesia. Major hemoptysis: secure airway; bronchoscopy urgently; interventional bronchoscopy or bronchial artery embolization if massive. Consider CT angiography to identify source.
7
Complications
Rates, risk factors, and management
Common Complications
- Pneumothorax (20–40% incidence) — most common complication; 10–15% require chest tube; risk factors: emphysema, bullous disease, traversed fissures, multiple probe passes, peripheral location
- Pleural effusion — reactive; common post-ablation; no intervention unless symptomatic (progressive dyspnea or large effusion); thoracentesis if needed
- Pain — pleuritic or chest wall; expected; NSAIDs and opioids PRN; severe chest wall pain with chest wall ablation may require nerve block
Serious Complications
- Pulmonary hemorrhage — usually self-limiting intrapulmonary; bronchovascular fistula with major hemoptysis rare (<1%); bronchial artery embolization or surgery if massive
- Bronchopleural fistula — rare; persistent air leak >5 days; chest tube; surgical consultation; risk higher with central tumors and prior radiation
- Thermal injury to adjacent structures — diaphragm, pericardium, intercostal nerve; hydrodissection with D5W reduces risk
- Local recurrence — 15–30% for lesions >2 cm at 1 year; re-ablation or SBRT referral
Local Control by Tumor Size — Summary
| Tumor Size | 2-Year Local Control Rate | Recommendation |
|---|---|---|
| ≤2 cm | >90% | Optimal candidate; ablation strongly preferred |
| 2–3 cm | 65–75% | Acceptable; discuss SBRT as alternative or sequential therapy |
| >3 cm | <50% | Poor local control; SBRT preferred unless ablation uniquely indicated |
8
Critical Pearls
High-yield clinical guidance and pitfall avoidance
★
Size is the strongest predictor of local control.
≤2 cm: >90% local control at 2 years; 2–3 cm: 65–75%; >3 cm: <50%. Patient selection based on lesion size is the single most important determinant of procedural success. Do not ablate >3 cm tumors unless SBRT is unavailable or specifically contraindicated.
★
Concurrent biopsy saves a procedure.
Coaxial technique: advance coaxial needle to lesion, obtain core biopsy through inner needle, then advance ablation probe through the same coaxial access. Eliminates a separate diagnostic procedure and confirms histology before definitive treatment begins.
★
Ipsilateral side down positioning.
Placing the ablated lung in the dependent position reduces pneumothorax tracking toward the pleural surface, keeps any blood in the lung parenchyma rather than tracking to the pleura, and makes chest tube placement easier if needed. Preferred for most cases over prone positioning.
★
MWA preferred over RFA for lung.
Microwave produces larger, more reproducible ablation zones with less susceptibility to heat sink from pulmonary vasculature. Faster procedure times (5–10 min vs 15–20 min for RFA). Particularly advantageous for tumors 2–3 cm or near vessels >3 mm.
★
GGO halo is not tumor — do not mistake it for residual disease.
Post-ablation GGO represents reactive inflammation and hemorrhage, not viable tumor. The GGO progressively retracts on follow-up CT over 3–6 months. Stable or retracting GGO = treatment success. Growing enhancement or solid nodule within or at the margin = recurrence; biopsy to confirm before re-treatment.
★
SBRT and ablation have similar local control for stage I NSCLC.
For inoperable stage I NSCLC patients, SBRT and percutaneous ablation achieve comparable local control rates in prospective studies. Ablation is specifically preferred when: prior chest radiation (SBRT reirradiation risky), pacemaker or ICD present (SBRT dose-volume constraints), or when concurrent tissue biopsy is needed in the same setting.
9
References & Resources
Related procedures, guidelines, and primary literature
Key Guidelines
- SIR / CIRSE Standards of Practice: Image-Guided Tumor Ablation of Lung Tumors — indications, technical standards, and quality improvement
- NCCN Clinical Practice Guidelines: Non-Small Cell Lung Cancer — ablation as option for medically inoperable stage I NSCLC
- ACR Appropriateness Criteria: Nonsurgical Treatment for Locally Advanced NSCLC
Primary References
- Faintuch S, Salazar GM, eds. Interventional Oncology. Thieme; 2016. Ch. 3: McGraw C et al. Lung Tumor Ablation.
- Lencioni R, Crocetti L, Cioni R, et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol. 2008;9(7):621–628.
- Lanuti M, Sharma A, Digumarthy SR, et al. Radiofrequency ablation for treatment of medically inoperable stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137(1):160–166.
- Hiraki T, Gobara H, Iishi T, et al. Percutaneous radiofrequency ablation for clinical stage I non-small-cell lung cancer: results in 20 nonsurgical candidates. J Thorac Cardiovasc Surg. 2007;134(5):1306–1312.
- Pusceddu C, Sotgia B, Fele RM, Melis L. CT-guided thin needles percutaneous cryoablation (CA) in patients with primary and secondary lung tumors. Eur J Radiol. 2013;82(5):e246–e253.